This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data Presented At 49th EASD Annual Meeting Show Treatment With Lilly's Investigational Dulaglutide Resulted In Improved Patient-Reported Health Outcomes









BARCELONA, Spain, Sept. 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive patient-reported health outcomes from a Phase III clinical trial of dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. These results will be presented at the 49 th European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, Spain. 

In addition to reductions in HbA1c (hemoglobin A1c) levels and weight at 26 and 52 weeks with dulaglutide 1.5 mg, 1 dulaglutide-treated patients reported significant, positive improvements compared to baseline across several patient-reported indicators of diabetes management, measured using validated questionnaires, including:

  • satisfaction with treatment and rates of perceived hyperglycaemia as measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ);
  • weight-related self-perception (Impact of Weight on Self-Perception (IW-SP) and Ability to Perform Physical Activities of Daily Living Questionnaires (APPADL)); and
  • perceived current health status (EuroQoL 5-Dimension Questionnaire (EQ-5D)). 2

"Patients' perception of how diabetes treatment may affect their lives is an important consideration when choosing a medication. We are pleased that in this study, patients treated with dulaglutide reported improvements in several patient-reported outcome measures," said Gwen Krivi, Ph.D., vice president, Lilly Diabetes product development. "These results, coupled with dulaglutide's positive clinical data, suggest that, if approved, our investigational once-weekly GLP-1 may be an attractive treatment option for patients with type 2 diabetes."

The patient-reported outcomes from the AWARD-1 trial showed that treatment satisfaction, as measured by the DTSQ, was significantly higher with dulaglutide compared to baseline, and was significantly greater compared to placebo and exenatide twice-daily at 26 weeks. Significant improvements were also seen compared to baseline and exenatide twice-daily at 52 weeks. 2

Clinical results from the AWARD-1 trial showed that treatment with dulaglutide 1.5 mg led to improvements in HbA1c levels and weight reductions. 1 Dulaglutide-treated patients also demonstrated significant improvements compared to baseline and exenatide twice-daily in perceived hyperglycaemia scores (using DTSQ) at 26 and 52 weeks. 2

Patients in the study noted significant improvements in weight-related self-perception (IW-SP) compared to baseline at 26 weeks, which persisted through one year of treatment. These improvements were not significantly different between all treatment groups. 2 There were no significant differences in the ability to perform physical activities of daily living (APPADL) between dulaglutide-treated patients compared to baseline, placebo or exenatide-treated patients. 2

Treatment with dulaglutide, as well as with exenatide twice-daily, led to significant improvements in perceptions of current health status (EQ-5D) compared to baseline at 26 weeks; these improvements with dulaglutide 1.5 mg as well as exenatide twice-daily were also significant compared to placebo. Significant improvements were also seen compared to baseline at one year, with no significant differences between dulaglutide and exenatide twice-daily.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs